1. Badami S, Moorkoth S, Rai SR, Kannan E, Bhojraj S. Antioxidant activity of Caesalpinia sappan heartwood. Biol Pharm Bull. 2003; 26:1534-1537.
2. Hikino H, Taguchi T, Fujimura H, Hiramatsu Y. Antiinflammatory principles of Caesalpinia sappan wood and of Haematoxylon campechianum wood. Planta Med 1977.
3. Kim E-C, Hwang Y-S, Lee H-J, Lee S-K, Park M-H, Jeon B-H, et al. Caesalpinia sappan induces cell death by increasing the expression of p53 and p21WAF1/CIP1 in head and neck cancer cells. Am J Chin Med. 2005; 33:405-414.
4. Sireeratawong S, Piyabhan P, Singhalak T, Wongkrajang Y, Temsiririrkkul R, Punsrirat J, et al. Toxicity evaluation of sappan wood extract in rats. J Med Assoc Thai 2011; 93:50.
5. Wu J, Hou J, Zhang M, Zou Y, Yu B, editors. Protosappanin a, an immunosuppressive constituent from a Chinese herb, prolongs graft survival and attenuates acute rejection in rat heart allografts. Transplantation proceedings; 2008: Elsevier.
6. Wu J, Zhang M, Jia H, Huang X, Zhang Q, Hou J, et al. Protosappanin A induces immunosuppression of rats heart transplantation targeting T cells in grafts via NF-κB pathway. Naunyn Schmiedebergs Arch Pharmacol 2010; 381:83-92.
7. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis. 2003; 170:191-203.
8. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis. 1994; 106:83-97.
9. Friedman R, Moore S, Singal D. Repeated endothelial injury and induction of atherosclerosis in normolipemic rabbits by human serum. Lab Invest. 1975; 32:404-415.
10. Hu M-Y, Li Y-L, Jiang C-H, Liu Z-Q, Qu S-L, Huang Y-M. Comparison of lycopene and fluvastatin effects on atherosclerosis induced by a high-fat diet in rabbits. Nutrition. 2008; 24:1030-1038.
11. Moazed TC, Campbell LA, Rosenfeld ME, Grayston JT, Kuo C-c. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E—deficient mice. J Infect Dis 1999;180:238-241.
12. Thirumalai T, Tamilselvan N, David E. Hypolipidemic activity of Piper betel in high fat diet induced hyperlipidemic rat. J Acute Disease 2014; 3:131-135.
13. ørgen Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease an eight-year follow-up in the Copenhagen male study. Circulation 1998; 97:1029-36.
14. Maseri A. Inflammation, atherosclerosis, and ischemic events—exploring the hidden side of the moon. N Engl J Med 1997; 336:1014-1016.
15. McKellar GE, McCarey DW, Sattar N, McInnes IB. Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol 2009; 6:410-417.
16. Haddy N, Sass C, Droesch S, Zaiou M, Siest G, Ponthieux A, et al. IL-6, TNF-α and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort. Atherosclerosis 2003; 170:277-283.
17. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148:209-214.
18. Klinghammer L, Urschel K, Cicha I, Lewczuk P, Raaz-Schrauder D, Achenbach S, et al. Impact of telmisartan on the inflammatory state in patients with coronary atherosclerosis–influence on IP-10, TNF-α and MCP-1. Cytokine 2013; 62:290-296.
19. Loftus I, Naylor A, Bell P, Thompson M. Matrix metalloproteinases and atherosclerotic plaque instability. Br J Surg 2002;89:680-694.
20. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008;75:346-359.
21. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases structure, function, and biochemistry. Circ Res 2003; 92:827-839.
22. Cooper M, Lindholm P, Pieper G, Seibel R, Moore G, Nakanishi A, et al. Myocardial nuclear factor-κB activity and nitric oxide production in rejecting cardiac allorafts Transplantation 1998; 66:838-844.
23. Brand K, Page S, Walli AK, Neumeier D, Baeuerle PA. Role of nuclear factor‐kappa B in atherogenesis. Exp Physiol 1997; 82:297-304.
24. Baldwin Jr AS. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 1996; 14:649-681.
25. Gupta S, Pablo AM, c Jiang X, Wang N, Tall AR, Schindler C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 1997; 99:2752.
26. Jones SP, Gibson MF, Rimmer DM, Gibson TM, Sharp BR, Lefer DJ. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol 2002; 40:1172-1178.
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. Methods 2001; 25:402-408.
28. Jessberger R, Podust V, Hubscher U, Berg P. A mammalian protein complex that repairs double-strand breaks and deletions by recombination. J Biol Chem 1993; 268:15070-15079.
29. Crouse JR, Raichlen JS, Riley WA, Evans GW, Palmer MK, O’Leary DH, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007; 297:1344-53.
30. Laakso M, Sarlund H, Salonen R, Suhonen M, Pyörälä K, Salonen JT, et al. Asymptomatic atherosclerosis and insulin resistance. Arterioscler Thromb 1991;11:1068-1076.
31. Soh J, Iqbal J, Queiroz J, Fernandez-Hernando C, Hussain MM. MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion. Nat Med 2013; 19:892-900.
32. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21:1876-1890.
33. Li S-L, Zhang Y, Lin W, Liu J, Chen S-Y, Meng S, et al. Relationship between markers of inflammaion and serum lipd levels in healthy persons and patients with pure hyperlipemia. Chin J Cardiovasc Rehabil Med 2010; 19:227.
34. Chen X, Xun K, Chen L, Wang Y. TNF‐α, a potent lipid metabolism regulator. Cell Biochem Funct 2009; 27:407-416.
35. Feingold KR, Grunfeld C. Role of cytokines in inducing hyperlipidemia. Diabetes 1992;41(Supplement 2):97-101.
36. Libby P, Ridker PM. Novel inflammatory markers of coronary risk theory versus practice. Circulation 1999; 100:1148-1150.
37. Van Gaal LF, Mertens IL, Christophe E. Mechanisms linking obesity with cardiovascular disease. Nature 2006;444:875-880.